人体测量与代谢变量同管腔型早期乳腺癌肿瘤特征及基因组风险的关联:多中心前瞻性研究结果
PRO BONO研究纳入248例激素受体阳性/HER2阴性早期乳腺癌患者,评估Oncotype DX对治疗决策的影响并探索基因组风险、肿瘤特征与代谢指标的关系。Oncotype DX使化疗使用减少47.7%,复发评分与BMI无关,但BMI≥30及较高GLP-1水平与更大肿瘤独立相关。
要点
- Oncotype DX检测使激素受体阳性/HER2阴性早期乳腺癌化疗使用减少47.7%。
- 复发评分与BMI无显著关联,但与血清甘油三酯正相关、与GIP负相关。
- BMI≥30及GLP-1>148.85pg/ml与肿瘤>2cm的几率独立增加相关。
核心结论
- 复发评分结果显著影响激素受体阳性/HER2阴性早期乳腺癌的治疗决策,复发评分与BMI无关,但不良代谢谱和肥胖相关标志物与更大肿瘤相关,作者认为需进一步研究代谢谱与乳腺癌生物学之间的联系。
研究设计与样本
- 多中心前瞻性研究,纳入2019至2021年接受Oncotype DX检测的激素受体阳性/HER2阴性早期乳腺癌患者248例,收集BMI、肿瘤特征、代谢分析物和复发评分,记录检测前后治疗推荐并用Cohen Kappa评估一致性。
主要发现
- 248例早期乳腺癌患者中,Oncotype DX检测使化疗使用减少47.7%。
- 较高复发评分与血清甘油三酯正相关、与GIP负相关(均p<0.05)。
- 患者BMI与复发评分结果无显著关联。
- 肿瘤大小与BMI正相关(p=0.0286),并与瘦素(p=0.0079)、PAI-1(p=0.0083)、C肽(p=0.0124)、GIP(p=0.0036)、GLP-1(p=0.0476)、胰高血糖素(p=0.0224)和胰岛素(p=0.0327)血清水平正相关。
- BMI≥30和较高GLP-1水平(>148.85pg/ml)与更大肿瘤大小(>2cm)的几率独立增加相关。
关键数值与推荐
- Oncotype DX检测前后治疗推荐一致性采用Cohen Kappa评估。
- 关联检验采用卡方检验和Spearman相关。
- BMI≥30和GLP-1>148.85pg/ml为与肿瘤>2cm独立相关的阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hormone receptor-positive (HR+)/HER2-negative (HER2-) early-stage breast cancers (EBC) are treated with adjuvant endocrine therapy (ET), with chemotherapy (CT) reserved for high-risk cases. Obesity is linked to increased recurrence risk. The Oncotype DX® assay predicts prognosis and CT benefit. The PRO BONO study evaluated Oncotype DX test's impact on treatment decisions and explored associations between genomic risk, tumor features, and patient metabolic profiles. MATERIALS AND METHODS: Patients with HR+ /HER2-EBC undergoing Oncotype DX testing were enrolled. Body mass index (BMI), tumor characteristics (ER, PR, Ki67, grading, size, nodal status), a large panel of metabolic analytes, and Oncotype DX Recurrence Score® (RS) results were collected. Treatment recommendations (ET vs CT-ET) were recorded pre- and post-Oncotype DX, and concordance was determined using Cohen's Kappa. Associations were tested using Chi-Square test and Spearman Correlation. RESULTS: Of the 248 EBC patients (2019-2021), Oncotype DX testing reduced CT use by 47.7 %. Higher RS positively correlated with serum triglycerides and inversely with GIP (all p < 0.05). No significant association was found between patient BMI and RS result. Conversely, tumor size positively correlated with BMI (p = 0.0286) and with serum levels of leptin (p = 0.0079), PAI-1 (p = 0.0083), C-peptide (p = 0.0124), GIP (p = 0.0036), GLP-1 (p = 0.0476), glucagon (p = 0.0224), and insulin (p = 0.0327). A BMI≥ 30 and higher GLP-1 levels (>148.85pg/ml) were independently associated with increased odds of having larger tumor size (>2 cm). CONCLUSIONS: Recurrence Score result significantly impacts treatment decisions in HR+ /HER2-EBC. RS result was not associated with BMI, although unfavorable metabolic profiles and obesity-related markers correlated with larger tumors. These findings highlight the need to further investigate the link between metabolic profiles and breast cancer biology.
引用
- De Placido P, Di Rienzo R, Pietroluongo E, et al. Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study. Eur J Cancer. 2025. PMID: 40220739. doi:10.1016/j.ejca.2025.115409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。